RESUMO
Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer remains the leading cause of death from gynecologic cancer. In the last decade, there have been important advances both in systemic and surgical treatment. However, there is no doubt that the incorporation of PARP inhibitors as maintenance after the response to platinum-based chemotherapy, first in recurrent disease and recently also in first line, will change the natural history of the disease.The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of ovarian cancer, and to provide evidence-based recommendations for clinical practice.
Assuntos
Carcinoma Epitelial do Ovário/diagnóstico , Carcinoma Epitelial do Ovário/terapia , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/terapia , Antineoplásicos Imunológicos/uso terapêutico , Bevacizumab/uso terapêutico , Carcinoma Epitelial do Ovário/patologia , Quimioterapia Adjuvante/métodos , Ensaios Clínicos Fase III como Assunto , Procedimentos Cirúrgicos de Citorredução/métodos , Feminino , Humanos , Quimioterapia de Manutenção/métodos , Oncologia , Recidiva Local de Neoplasia/tratamento farmacológico , Recidiva Local de Neoplasia/cirurgia , Estadiamento de Neoplasias/métodos , Neoplasias Ovarianas/patologia , Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Sociedades Médicas , EspanhaRESUMO
In the original version of this article Figure 1 was shown incorrectly. The correct Figure 1 is shown here.
RESUMO
Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defined and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies.
Assuntos
Neoplasias do Endométrio/terapia , Quimioterapia Adjuvante/métodos , Feminino , Humanos , Radioterapia Adjuvante/métodosRESUMO
Because of advances in the understanding of histological and molecular characteristics in ovarian cancer, it is now possible to recognize the existence of five subtypes, which in turn has allowed a more refined therapeutic approach and better design of clinical trials. Each of these five subtypes has specific histological features and a particular biomarker expression, as well as mutations in different genes, some of which have prognostic and predictive value. CA125 and HE4 are examples of ovarian cancer biomarkers used in the diagnosis and follow-up of these malignancies. Currently, somatic or germinal mutations on BRCA1 and BRCA2 genes are the most important biomarkers in epithelial ovarian cancer having prognostic and predictive value. This article will review the histological and molecular characteristics of the five subtypes of ovarian cancer, describing the most important biomarkers and mutations that can guide in diagnosis, screening and tailored treatment strategy.
Assuntos
Biomarcadores Tumorais/análise , Neoplasias Epiteliais e Glandulares/diagnóstico , Neoplasias Ovarianas/diagnóstico , Carcinoma Epitelial do Ovário , Feminino , HumanosRESUMO
Abstract: Ecuador is considered the fishing capital of the Southeastern tropical Pacific with more than 900 native species. Cichlasoma festae represents an economic important freshwater species of much local use. Thus, in this study, our goal was to characterize this fish species during juvenile stages, as the first step for its conservation and valuation, and also for the preparation of proposals for sustainable rural development and formulation of plans for environmentally responsible fisheries management. The study lasted 25 weeks and was undertaken in the ictiohidrographic area of Province of Los Rios, which accounts for 35 % of native fish species in Ecuador. Weekly, the individual biometric parameters total length (L), body width (BW) and body depth (BD) of 90 juveniles of C. festae were measured. Growth was determined using non-linear biological regression models. The average standard length varied between 6.30 cm and 12.25 cm and the average weight varied between 4.99 and 35.71 g. The length-weight relationship was best fit by the equation lnW = -3.92 + 2.96 ln(L), and the species presented negative allometric growth. Finally, the best fit for the growth of C. festae was the Von Bertalanffy's model where L∞ = 19.758 cm, k = 0.028 cm week-1 and t0 = -14.463 week-1. We concluded that to support sustainable and reliable fisheries production studies, the growth record from length may be obtained with standard methods as those evaluated in this study, or may be obtained with new safer tools such as photogrammetry. Rev. Biol. Trop. 65 (3): 1185-1193. Epub 2017 September 01.
Resumen: Ecuador se considera la capital pesquera del Pacífico tropical suroriental con más de 900 especies nativas. Cichlasoma festae representa una importante especie de agua dulce de gran uso local. Por lo tanto, en este estudio, nuestro objetivo fue caracterizar esta especie durante la etapa juvenil, como primer paso para su conservación y valoración, así como para la preparación de propuestas para el desarrollo rural sostenible y la formulación de planes para una gestión pesquera ambientalmente responsable. El estudio duró 25 semanas y se llevó a cabo la zona ictiohidrográfica de la Provincia de Los Ríos, que representa el 35 % de las especies nativas en Ecuador. Semanalmente, se midieron los parámetros biométricos individuales longitud total (L), ancho corporal (BW) y profundidad corporal (BD) de 90 juveniles de C. festae. El crecimiento se determinó utilizando modelos de regresión biológicos no lineales. La longitud media estándar varió entre 6.30 y 12.25 cm y el peso promedio varió entre 4.99 y 35.71 g. La relación longitudpeso se ajustó a la ecuación lnW = -3.92 + 2.96 ln(L), y la especie presentó crecimiento alométrico negativo. Finalmente, el mejor ajuste para el crecimiento de C. festae fue el modelo de Von Bertalanffy donde L∞ = 19.758 cm, k = 0.028 cm week -1 y t0 = -14.463 week -1. Concluimos que el registro de crecimiento de la longitud podría estar asociado a la fotogrametría como una herramienta para el desarrollo de una producción pesquera sostenible y segura.
RESUMO
Allele frequency distribution and statistical parameters of forensic efficiency concerning the Investigator Argus X-12 kit (Qiagen, Hilden, Germany) were determined in a total sample of 641 unrelated Mexican females, including two Mestizo-admixed- populations (n=309) and seven Amerindian groups (n=332) from the main regions of the country. Most of the 12 X-STRs were in agreement with Hardy-Weinberg expectations in all nine Mexican populations. The power of discrimination in females (PD) and Median exclusion chance for trios (MECT) and duos (MECD) of this genetic system based on X-STRs were >99.99%. Although Mexican populations showed significant pairwise differentiation, a closer relationship was evident between Amerindian groups and nearby Mestizos, in agreement with historical records, previous genetic studies, and X-linked inheritance pattern expectations.
Assuntos
Impressões Digitais de DNA , Frequência do Gene , Genética Populacional , Indígenas Norte-Americanos/genética , Feminino , Humanos , México , Repetições de MicrossatélitesRESUMO
Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer (OC) is the first cause of death due to gynecological cancer and the fifth cause of death for cancer in women in Spain. The aim of this guideline is to summarize the current evidence and to give evidence-based recommendations for clinical practice.
Assuntos
Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/terapia , Guias de Prática Clínica como Assunto , Feminino , Humanos , EspanhaRESUMO
Cervical cancer (CC) is the second most common cancer worldwide, strongly linked to high-risk human papilloma virus infection. Although screening programs have led to a relevant reduction in the incidence and mortality due to CC in developed countries, it is still an important cause of mortality in undeveloped countries. Clinical stage is still the most relevant prognostic factor. In early stages, the primary treatment is surgery or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. In the setting of recurrent or metastatic CC, for the first time ever, the combination of chemotherapy plus bevacizumab prolongs the overall survival beyond 12 months. Therefore, this regimen is considered by most of the oncologist a new standard of care for metastatic/recurrent CC.
Assuntos
Guias de Prática Clínica como Assunto/normas , Neoplasias do Colo do Útero/diagnóstico , Neoplasias do Colo do Útero/terapia , Ensaios Clínicos como Assunto , Terapia Combinada , Gerenciamento Clínico , Detecção Precoce de Câncer , Feminino , Humanos , Oncologia , Estadiamento de Neoplasias , Prognóstico , Sociedades MédicasRESUMO
Ovarian cancer is the leading cause of death due to gynecological cancer and the 5th cause of death for cancer in women in Europe. Optimal management of patients with ovarian cancer needs the participation of a well-trained multidisciplinary team. In the last few years, we have observed a significant improvement in the knowledge of the molecular biology of the different histotypes of ovarian cancer that will probably change our standard of care in the forthcoming years. In this Guideline, we summarize the most current evidence for the medical management of ovarian cancer.